

Product datasheet for TL310609V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Parkin (PARK2) Human shRNA Lentiviral Particle (Locus ID 5071)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: Parkin (PARK2) Human shRNA Lentiviral Particle (Locus ID 5071)

Locus ID: 5071

Synonyms: AR-JP; LPRS2; PARK2; PDJ

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: PARK2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: <u>BC022014, NM 004562, NM 013987, NM 013988, NM 013988.1, NM 013988.2, NM 004562.1</u>

NM 004562.2, NM 013987.1, NM 013987.2, BC022014.2, NM 013988.3, NM 013987.3,

NM 004562.3

UniProt ID: <u>060260</u>

Summary: The precise function of this gene is unknown; however, the encoded protein is a component

of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Mutations in this gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing of this gene produces multiple transcript variants encoding distinct isoforms. Additional splice variants of this gene have been described but currently lack transcript support. [provided by RefSeq, Jul

2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).